DJIA 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%

Antares Pharma, Inc.

NASDAQ: ATRS

4.06 0.08 (2.01%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ATRS $4.06 2.01%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.00
Previous Close $3.98
Daily Range $3.99 - $4.07
52-Week Range $2.60 - $5.58
Market Cap $512.3M
P/E Ratio -30.62
Dividend (Yield) $0.00 (0.0%)
Volume 1,304,383
Average Daily Volume 981,380
Current FY EPS -$0.10

Sector

Healthcare

Industry

Healthcare Information Services

Antares Pharma, Inc. (ATRS) Description

The Company develops, produces and markets pharmaceutical delivery products, including transdermal gels, oral fast melting tablets and reusable needle-free and disposable mini-needle injector systems. Website: http://www.antarespharma.com/

News & Commentary

3 Most Important Upcoming FDA Decisions of 2013

The Food and Drug Administration will decide on drugs developed by Merck, Antares Pharmaceuticals, and GlaxoSmithKline in the coming months.

Antares: Reiteration Of My Buy Recommendation

Contraceptive Ring: Another Under-The-Radar Catalyst For Antares

Antares Pharma to Present at the Bank of America Merrill Lynch 2013 Healthcare Conference

Antares Pharma Whiffs on Revenues

Just the facts, Fool.

Antares Pharma Management Discusses Q1 2013 Results - Earnings Call Transcript

Antares Q1 Results Unimpressive, but Otrexup Could Be Catalyst

Antares Pharma didn't impress the market with its Q1 results, but a pending Food and Drug Administration decision on Otrexup might be a game changer for this small biotech.

Antares Pharma Reports First Quarter 2013 Operating and Financial Results

Antares: Challenger Emerging Against 400-Year Old Condom

Antares Pharma to Host First Quarter 2013 Operating and Financial Results Conference Call

See More ATRS News...

ATRS's Top Competitors

ATRS $4.06 (2.01%)
Current stock: ATRS
$0.00 (0.00%)
Current stock:
MDT $49.84 (0.40%)
Current stock: MDT
COV $65.77 (0.15%)
Current stock: COV